Lyn Brant, APRN
Nurse Practitioner · Bethany, OKNPI 1275567695
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $40.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amarin Pharma, Inc.$582
- Novo Nordisk$518
- Merck$440
- Esperion Therapeutics, Inc.$424
- Teva Pharmaceuticals USA, Inc.$381
- plus $3K from 25 others
What the payments were for
- Food & beverage$6,321100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $1,481 |
| Amarin Pharma, Inc. | 34 | $582 |
| Novo Nordisk | 7 | $518 |
| Merck | 25 | $440 |
| Esperion Therapeutics, Inc. | 7 | $424 |
| Teva Pharmaceuticals USA, Inc. | 6 | $381 |
| Amgen | 6 | $330 |
| Xeris Pharmaceuticals, Inc. | 5 | $308 |
| Optinose US, Inc. | 2 | $236 |
| Biohaven Pharmaceuticals, Inc. | 2 | $216 |
| GSK | 3 | $151 |
| Boehringer Ingelheim | 2 | $140 |
| AbbVie | 2 | $132 |
| Johnson & Johnson | 1 | $125 |
| Bayer | 1 | $119 |
| Astellas Pharma US Inc | 1 | $118 |
| Althera Pharmaceuticals LLC | 2 | $110 |
| Novartis | 5 | $94 |
| Lilly USA, LLC | 4 | $68 |
| Medtronic | 1 | $67 |
| Kowa Pharmaceuticals America, Inc. | 3 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Ultragenyx Pharmaceutical Inc. | 2 | $39 |
| Abbott | 2 | $36 |
| Averitas Pharma Inc. | 1 | $25 |
| Antares Pharma, Inc. | 1 | $23 |
| Pfizer | 1 | $20 |
| Baxter Healthcare | 1 | $18 |
| Dexcom, Inc. | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| W. L. Gore & Associates, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,332 in reported general payments places this provider in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 20 | $32,801 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $24,000 |
| RybelsusSemaglutide | 15 | $23,754 |
| JardianceEmpagliflozin | 18 | $21,865 |
| MounjaroTirzepatide | 19 | $21,293 |
| MyrbetriqMirabegron | 17 | $10,560 |
| EliquisApixaban | 13 | $7,426 |
| GemtesaVibegron | 12 | $6,606 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $4,030 |
| SynthroidLevothyroxine Sodium | 25 | $2,457 |
| Montelukast Sodium | 118 | $2,027 |
| Omega-3 Acid Ethyl Esters | 17 | $2,010 |
| Rosuvastatin Calcium | 164 | $2,010 |
| Atorvastatin Calcium | 134 | $1,749 |
| Pravastatin Sodium | 38 | $1,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,481 | $32,80120 claims |
| GSKTrelegy Ellipta | $151 | $24,00030 claims |
| Novo NordiskRybelsus | $518 | $23,75415 claims |
| Boehringer IngelheimJardiance | $140 | $21,86518 claims |
| Lilly USA, LLCMounjaro | $68 | $21,29319 claims |
| Astellas Pharma US IncMyrbetriq | $118 | $10,56017 claims |
| PfizerEliquis | $20 | $7,42613 claims |
| AbbVieSynthroid | $132 | $2,45725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Other nurse practitioner in Bethany
- Jenny GuthrieTulsa$106K
- Leah MeltonNorman$87K
- Sara GoreOklahoma City$52K
- Teisha GalleglyMoore$43K
- Stacy NewberryTulsa$28K
- Russell RoomsOklahoma City$24K
- Grant YoungOklahoma City$15K
- Monica LawsonNorman$15K
- Amanda SmallTulsa$14K
- Janelle WagnerOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.